A Singular Focus on Cell Therapy
Founded in 2009 as a pioneer in cell therapy research, Kite’s leadership position in the immuno-oncology space was solidified with our research and development agreement with the National Cancer Institute in 2012 and when the commercial manufacturing site opened in El Segundo in 2016. Since our acquisition by biopharma leader Gilead Sciences in October 2017, our combined strength has accelerated the advancement of our pipeline, including the launch of YESCARTA® (axicabtagene ciloleucel) and TECARTUS® (brexucabtagene autoleucel), and has expanded the impact of our strategic partnerships.
As an independent operating company since 2019, we prioritize innovative R&D with the full resources, capabilities, and trust of Gilead. As a vital part of Gilead — a founding member of the Foundation for the NIH’s Partnership for Accelerating Cancer Therapies — we are devoted to advancing the understanding of cell therapy as a transformational treatment option for cancer.
Building on our achievements as the first approved therapy for adults with diffuse large B-cell lymphoma (DLBCL), we are now working to accelerate the advancement of CAR T and TCR cellular therapy platforms and ushering in the future of immunomodulation. The combined strength of Kite and Gilead allows us to remain innovative, agile, and ambitious in our mission to keep improving the lives of people with all types of cancer.
For more on Kite’s acquisition by Gilead Sciences in 2017, read the press release.